• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. Investing
  1. Tuttle Tactical Management Weekly Market Commentary

    Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...

  2. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  3. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

  4. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

  5. Dodge & Cox: Pharma Stocks Showing Value

    As incomes rise, emerging-markets consumers can afford more and better medications driving attractive growth in the pharmaceuticals sector, say the managers of Dodge & Cox International Stock.

  6. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

  7. Does This ETF Exceed the Sum of Its Parts?

    We look at how a biotech ETF holds up in an iffy climate for those stocks.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.